A Randomized Multicenter Study Comparing a Paclitaxel Drug-eluting Balloon with a Paclitaxel-eluting Stent in Small Coronary Vessels: the BELLO (Balloon Elution and Late Loss Optimization) Study
Overview
Authors
Affiliations
Objectives: The aim of this study was to evaluate the efficacy of drug-eluting balloons (DEB) compared with paclitaxel-eluting stents (PES) for the reduction of restenosis in small vessels.
Background: DEB have been shown to be effective in the treatment of coronary in-stent restenosis, but data are limited regarding their efficacy in de novo disease.
Methods: BELLO (Balloon Elution and Late Loss Optimization) is a prospective, multicenter trial that randomized 182 patients with lesions located in small vessels (reference diameter <2.8 mm) to treatment with paclitaxel DEB and provisional bare-metal stenting (n = 90) or PES implantation (n = 92). The primary endpoint was noninferiority of angiographic in-stent (in-balloon) late loss with a delta of 0.25 mm. Secondary endpoints were angiographic restenosis, target lesion revascularization, and major adverse cardiac events (MACE; death, myocardial infarction, target vessel revascularization) at 6 months.
Results: Baseline characteristics were well matched, except for a smaller vessel size in the DEB group (2.15 ± 0.27 mm vs. 2.25 ± 0.24 mm; p = 0.003). The majority (89%) of lesions involved vessels with a diameter <2.5 mm. Bailout stenting was required in 20% of lesions in the DEB group. The primary endpoint of in-stent (in-balloon) late loss was significantly less with DEB compared with PES (0.08 ± 0.38 mm vs. 0.29 ± 0.44 mm; difference -0.21; 95% CI: -0.34 to -0.09; p(noninferiority) < 0.001; p(superiority) = 0.001). At 6 months, DEB and PES were associated with similar rates of angiographic restenosis (10% vs. 14.6%; p = 0.35), [corrected] target lesion revascularization (4.4% vs. 7.6%; p = 0.37), and MACE (10% vs. 16.3%; p = 0.21). [corrected].
Conclusions: Treatment of small-vessel disease with a paclitaxel DEB was associated with less angiographic late loss and similar rates of restenosis and revascularization as a PES. (Balloon Elution and Late Loss Optimization [BELLO]; Study NCT01086579).
Augustine M, Arain M, Mustafa M, Moradi I, Fredericks M, Rahman A Egypt Heart J. 2025; 77(1):26.
PMID: 40009140 PMC: 11865403. DOI: 10.1186/s43044-025-00621-7.
Coronary Dissection - Back to the Future - Finding Good in the Bad!.
Natarajan R, Corballis N, Merinopoulos I, Vassiliou V, Eccleshall S Heart Int. 2025; 18(2):14-23.
PMID: 39885932 PMC: 11781370. DOI: 10.17925/HI.2024.18.2.5.
Niu J, Wang K, Wang W, Liu Y, Yang J, Sun Y Rev Cardiovasc Med. 2025; 25(12):446.
PMID: 39742237 PMC: 11683689. DOI: 10.31083/j.rcm2512446.
Contemporary Use of Drug-Coated Balloons for Coronary Angioplasty: A Comprehensive Review.
Verde N, Ciliberti G, Pittorino L, Ferrone M, Franzese M, Russo M J Clin Med. 2024; 13(20).
PMID: 39458193 PMC: 11508324. DOI: 10.3390/jcm13206243.
Vessel Geometry Estimation for Patients with Peripheral Artery Disease.
Saeed H, Skalski A Sensors (Basel). 2024; 24(19).
PMID: 39409481 PMC: 11479335. DOI: 10.3390/s24196441.